
ã¢ã¡ãªã«ã§ã¯ããŸã ã«ãæ¯é±ãå¹³åã§300人以äžãæ°åã³ãããŠã€ã«ã¹ïŒCOVID-19ïŒã§æ»äº¡ããŠãããšèšãããŠããã
é廿°å¹Žéã«æ¯ã¹ããšå°ãªããã®ã®âŠ
ã¢ã¡ãªã«çŸç
察çäºé²ã»ã³ã¿ãŒïŒCDCïŒã®ããŒã¿ã«ãããšã4æã¯æ¯é±å¹³åã§çŽ350人ãCOVID-19ã§äº¡ããªã£ããšããã
ãã£ãšã2021幎1æã«ã¯ã1é±éã«2äž5974äººãæ»äº¡ããŠããããã®ããŒã¯æããé廿°å¹Žéã®æ¥ã®ææã®æ»è
æ°ã«æ¯ã¹ããšãçŸåšã¯äœãæ°Žæºãšãªã£ãŠããã
ãã¥ãŒã¯å€§åŠå»çã»ã³ã¿ãŒææçã»å°å
ç§ææã®ãããŒã»ã ãŒãã£ãŒå士ã¯ABCãã¥ãŒã¹ã«å¯ŸãããäŸç¶ãšããŠæ»è
ãåºãŠãããšããããšã¯ããŠã€ã«ã¹ããŸã èå»¶ããŠããã人ã
ãææãç¶ããŠãããšããããšã§ãããšè¿°ã¹ãCOVID-19ã¯äŸç¶ãšããŠé«ããªã¹ã¯ã®ãã人ã
ã«ãšã£ãŠè
åšã§ãããšææããŠããã
ã¯ã¯ãã³æ¥çš®çã®äœã
å°éå®¶ã«ããã°ãCOVID-19ã«ããæ»äº¡è
ãåºãŠããçç±ã¯ããã€ããããã¯ã¯ãã³æ¥çš®çã®äœããå
ç«åã®äœäžãæ²»çãåãã人ãå°ãªãããšãæãããããšããã
CDCã®ããŒã¿ã§ã¯ã2024ïœ25幎ã®ã·ãŒãºã³äžã4æ26æ¥ãŸã§ã®æç¹ã§ã18æ³ä»¥äžã®æäººã®ãã¡ãææ°ã®COVID-19ã¯ã¯ãã³ãæ¥çš®ããã®ã¯ããã23%ãåäŸã¯ããã13%ã ã£ãããã ã
çŸç
äºé²ã«éç¹ã眮ãã¢ããªã¢ç ç©¶æã®ã¯ã¯ãã³åŠè
ã§ããã°ã¬ãŽãªãŒã»ããŒã©ã³ãå士ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ãååã§ãªãå¯èœæ§ãããããããæ¯é±ã®COVIDã«ããæ»äº¡è
æ°ã®å¢å ã«ã€ãªãã£ãŠãããšè¿°ã¹ãã
ãŸãããŒã©ã³ãå士ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ã®äžã«ããé©åãªå
ç«åå¿ãçºçŸããŠããªã人ãããå¯èœæ§ããæéã®çµéãšãšãã«å
ç«ã匱ãŸããææãããããªã£ãŠããããšããŸãé«éœ¢ã«ããå
ç«èåãèµ·ããŠããå¯èœæ§ãææããŠããã
ãã®ããã¢ã¡ãªã«ã§ã¯ã65æ³ä»¥äžã®äººã«å¯ŸããŠãæ¹è¯ãããCOVIDã¯ã¯ãã³ã6ã«æééã§2åæ¥çš®ããããšãæšå¥šãããŠãããšããã
çç¶ãéããªããŸã§èšºå¯ãåãã
ãŸãçŸåšãCOVID-19ã®æ£è
ã®ããã«è€æ°ã®æãŠã€ã«ã¹è¬ãããããããã¯çç¶ãçŸããŠãã5æ¥ä»¥å
ã«æäžããªããã°ãªããªããéèå
ã«æäžããè¬ãã¬ã ãã·ãã«ãã®å Žåã¯ãçç¶ãçŸããŠãã7æ¥ä»¥å
ã«æäžããå¿
èŠãããã
ãããCOVID-19ã®æ£è
ã®äžã«ã¯ãçç¶ãåºãŠããã«ãããããããçç¶ãéããªããŸã§å»åž«ã®èšºå¯ãåããŠããªã人ãããããCOVID-19ã®æ€æ»ãåããŠããªãããã蚺æãèŠéãããããããŠããå Žåããããšããã
ã ãŒãã£ãŒå士ããå
šå¡ã宿çã«æ€æ»ãåããå¿
èŠã¯ãªããé«ãªã¹ã¯ã®äººã ããé »ç¹ã«æ€æ»ãåããã¹ãã ãšãã€ã€ãããææããŠããŠãçºèŠããããæ²»çãåããŠããªã人ãããããšã¯ç¢ºãã§ãããšè¿°ã¹ãŠãããïŒäºïŒ